Sacha Rothschild: How Patients With ES-SCLC Are Treated in Switzerland
Sacha Rothschild/LinkedIn

Sacha Rothschild: How Patients With ES-SCLC Are Treated in Switzerland

Sacha Rothschild, Head (Chefarzt) of the Center for Oncology and Hematology at Kantonsspital Baden, shared on LinkedIn:

“New publication: How patients with extensive-stage SCLC are treated in Switzerland, and where access still falls short.

I’m pleased to share our review, just published open access in Therapeutic Advances in Medical Oncology:

‘The evolving management of patients with extensive-stage small cell lung cancer in Switzerland: From regulatory access to bedside.’

For decades, platinum-etoposide was the only first-line option in ES-SCLC. Since 2019, chemo-immunotherapy, maintenance strategies and new options at relapse have changed this. The question now is how these advances actually reach patients.

21 authors from 13 Swiss hospitals and oncology centres, across all three language regions, reviewed Swiss registry data, the evidence, guidelines and regulatory sources.

The Review Offers

  • A Swiss treatment algorithm from first-line to later-line therapy,
  • A framework for second-line decisions: time to relapse, performance status, brain metastases, patient preferences and access,
  • A map of the Swiss route from Swissmedic approval to reimbursement.

One Key Message

Approval does not equal access. Reimbursement listing often follows 6-18 months after approval. In the meantime, access depends on case-by-case decisions under Art. 71a-d KVV, which means extra work for treating teams and outcomes that can vary between insurers and between centres. Fast approval alone does not guarantee timely and fair access for every patient.

This is a narrative, expert-informed review meant to support tumour board discussions. It is not a national guideline.

Many thanks to Nuria Mederos Alfonso for leading this work, to Peters Solange and Alessandra Curioni Fontecedro as senior authors, and to all co-authors.”

Title: The evolving management of patients with extensive-stage small cell lung cancer in Switzerland: From regulatory access to bedside.

Authors: Nuria Neisy Mederos Alfonso, Ulrich Richter, Michael Thomas Mark, Sebastian Kraus, Alexander Meisel, Jana Pankovics, Martina Imbimbo, Patrizia Froesch, Kira-Lee Koster, Sabine Schmid, Sacha I. Rothschild, Alex Friedlaender, Asteria Nikolopoulou, Alexandre Huber, Danny Kupka, Karim Abdelhamid, Valérie Mosimann, Nabila Ferahta, May-Lucie Meyer, Solange Peters, Alessandra Curioni-Fontecedro.

Full article.

You can also read: DeLLphi-305: Durvalumab + Tarlatamab Improves Survival in First-Line ES-SCLC.

Sacha Rothschild